Halozyme Therapeutics
HALO
$109.84
-0.86%
Halozyme Therapeutics, Inc. is a commercial-stage biotechnology company that develops and commercializes novel oncology therapies and, more importantly, monetizes its proprietary ENHANZE drug-delivery technology (recombinant human hyaluronidase, rHuPH20) through licensing and royalty agreements with major biopharmaceutical partners. Unlike traditional clinical-stage biotechs, Halozyme operates as a royalty-and-licensing platform whose economics are driven by subcutaneous formulation conversions of blockbuster drugs rather than by binary pipeline readouts, giving it an unusual hybrid profile of high-margin royalty streams layered on top of a smaller proprietary-product business. The current investor narrative centers on the explosive inflection in royalty revenue — Q2 2026 revenue of $481.0 million grew 47.7% year over year, and the stock gapped from roughly $86 to $103 on August 7, 2026, the session immediately following that print, as the market re-rated the durability and scale of the royalty base. Debate now hinges on whether this step-change is a sustainable platform trajectory or a lumpy, milestone-driven spike, with the elevated short ratio of 9.83 suggesting a meaningful cohort of investors positioned against the move.…
HALO
Halozyme Therapeutics
$109.84
Related headlines
Investment Opinion: Should I buy HALO Today?
The synthesized recommendation is Buy, with a clear thesis that Halozyme's royalty-driven platform is materially undervalued on forward earnings. The analyst consensus includes Buy/Outperform ratings from HC Wainwright, Citizens, TD Cowen, and Leerink Partners (upgraded August 7, 2026), with an average target price of $99.56. While the stock trades above this average, the forward PE of 10.57x and the 47.7% revenue growth trajectory suggest targets are lagging and likely to be revised upward.
The supporting evidence is compelling: revenue grew 47.67% YoY in Q2 2026 to $481.0 million, gross margin expanded to 83.54%, operating margin reached 59.80%, and trailing free cash flow is $806.2 million. The forward PE of 10.57x compares favorably to large-cap biotech royalty peers typically trading at 15-25x forward earnings, and the EV/Sales of 8.47x is mid-range. The company returned $332.7 million via buybacks in Q2 2026 alone, and the current ratio of 4.66 provides ample liquidity. The implied upside to the analyst high target of $115.00 is approximately 4.7%, but if earnings double as consensus suggests, the multiple could expand toward peer levels, implying significant upside.
The biggest risks that could invalidate the thesis are: (1) a deceleration in royalty growth below 20% YoY, which would challenge the platform narrative; (2) a major partner renegotiating or losing exclusivity, which would impair the royalty stream; and (3) multiple compression if the market re-rates biotech lower. This Buy would downgrade to Hold if forward PE exceeds 15x without commensurate earnings growth, or if revenue growth decelerates below 25% YoY. Conversely, it would upgrade to Strong Buy if the forward PE remains below 12x while revenue growth sustains above 40%. Relative to its own history, the stock has de-rated on sales (PS of 5.77x vs. 19.08x in Q2 2026 on the historical ratio series), suggesting it is undervalued on a revenue basis despite the price appreciation.
Sign up to view all
HALO 12-Month Price Forecast
Halozyme presents a compelling bull case anchored by a 47.7% YoY revenue growth inflection, exceptional margins, and a forward PE of only 10.57x that is deeply discounted relative to peers. The stock trades above the average analyst target of $99.56, but this reflects the mechanical lag of price targets after a blowout quarter, and upgrade activity in August suggests targets are being revised upward. The 9.83 short ratio creates potential for a squeeze if execution continues. However, the stock is priced for perfection near its 52-week high, and any royalty disappointment could trigger a sharp re-rating. I would upgrade to high confidence if Q3 2026 revenue growth exceeds 40% YoY and the forward PE remains below 12x; I would downgrade to neutral if revenue growth decelerates below 25% YoY or if a major partner renegotiates terms.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Halozyme Therapeutics's 12-month outlook, with a consensus price target around $102.11 and implied upside of -7.0% versus the current price.
Average Target
$102.11
0 analysts
Implied Upside
-7.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$78 - $130
Analyst target range
Nine analysts cover Halozyme, and the sentiment skews constructive: the institutional ratings log shows HC Wainwright reiterating Buy on September 2, 2026, Citizens at Market Outperform, TD Cowen at Buy, and — notably — Leerink Partners upgrading to Outperform from Market Perform on August 7, 2026, the day of the blowout Q2 print, while Wells Fargo remains the lone Equal Weight. The consensus average target price is $99.56, which sits below the current price of $109.86, implying roughly -9.4% downside to the mean target — a rare configuration where the stock has run past the average analyst's published fair value. That does not necessarily signal a bearish consensus; rather, it reflects the mechanical lag of price targets after a 47.7% revenue-growth quarter and a 53% one-year move, and the upgrade activity in August suggests targets are being revised upward rather than downward. The target range is wide, from a low of $70.00 to a high of $115.00, a spread of 64% of the low end, which signals genuine disagreement about the durability of the royalty inflection. The high target of $115.00 — still below the 52-week high of $116.85 — implies continued multiple expansion and successful conversion of the ENHANZE royalty pipeline into recurring revenue, while the low target of $70.00 prices in a scenario where royalty growth decelerates sharply, a major partner renegotiates or loses exclusivity, or the Q4 2025-style acquisition charge proves symptomatic of value-destructive capital allocation. Consensus estimated EPS of $9.38 (range $8.62-$10.00) and estimated revenue of $1.90 billion (range $1.78-$2.00 billion) frame the fundamental bar; the tightness of the EPS range relative to the wide price-target range suggests analysts broadly agree on near-term earnings power but disagree on the terminal multiple. With the stock trading above the average target and a 9.83 short ratio, the setup is asymmetric: continued execution likely forces both target upgrades and short covering, but any royalty disappointment would find the stock priced for perfection with limited analyst support beneath it.
Drowning in data?
Find the real signal!
Bulls vs Bears: HALO Investment Factors
The bull case currently has stronger evidence, anchored by accelerating revenue growth of 47.7% YoY, exceptional margins (83.5% gross, 59.8% operating), and a forward PE of only 10.57x that suggests the stock is undervalued on earnings power. The bear case rests on the stock trading above the average analyst target of $99.56, a stretched technical position near all-time highs, and a 9.83 short ratio that signals persistent skepticism. The single most important tension is whether the Q2 2026 royalty inflection represents a sustainable platform trajectory or a lumpy, milestone-driven spike — if the former, the forward multiple is far too low; if the latter, the stock is priced for perfection with limited downside support. Resolution of this debate will likely come from the next few quarterly prints and any partner updates on ENHANZE conversions.
Bullish
- Revenue growth accelerating at 47.7% YoY: Q2 2026 revenue of $481.0 million rose 47.67% year over year from $325.7 million in Q2 2025, and the sequential cadence confirms acceleration: $376.7M in Q1 2026, $451.8M in Q4 2025, and $354.3M in Q3 2025. This is not a one-off spike but a compounding royalty inflection.
- Forward PE of 10.57x is deeply discounted: Trailing PE of 25.49x compresses to a forward PE of just 10.57x based on consensus EPS of $9.38, implying the market expects earnings to more than double. That multiple is more typical of a mature, low-growth company than a platform growing revenue 47.7% YoY.
- Exceptional margins with royalty mix shift: Q2 2026 gross margin reached 83.54% and operating margin 59.80%, with net income of $229.9 million on a 47.8% net margin. Royalty revenue of $307.7 million is now the largest line, and because royalties carry near-zero incremental cost, each new partnered subcutaneous conversion drops through at very high incremental margins.
- Strong FCF and capital returns: Trailing free cash flow is $806.2 million, Q2 2026 operating cash flow was $240.9 million against just $4.2 million of capex, and the company repurchased $332.7 million of stock in Q2 2026 alone. The current ratio of 4.66 with $164.0 million of cash signals ample liquidity.
Bearish
- Stock trades above average analyst target: The consensus average target price is $99.56, implying roughly -9.4% downside from the current price of $109.86. This rare configuration means the stock has run past the average analyst's published fair value, leaving limited analyst support beneath it.
- Priced for perfection near 52-week high: At $109.86, the stock sits at roughly 88% of its 52-week range (low $61.23, high $116.85) and within 6% of its all-time high. This positioning leaves little margin for disappointment, and any royalty miss could trigger a sharp re-rating.
- Lumpy, partner-dependent revenue recognition: Revenue is heavily reliant on milestone payments and royalty streams from a concentrated set of biopharma partners. The Q4 2025 quarter saw a $355.2 million other-expense item tied to a $1.01 billion acquisition outflow, driving a $141.6 million net loss and negative EBITDA of $69.3 million, illustrating earnings volatility.
- Elevated short ratio signals skepticism: A short ratio of 9.83 indicates a meaningful cohort of investors positioned against the move, reflecting doubts about the sustainability of the royalty inflection. If growth decelerates, this short base could amplify downside through momentum-driven selling.
HALO Technical Analysis
Halozyme is in a powerful, sustained uptrend: the shares are up 53.24% over the trailing year, 56.25% year-to-date, and 70.35% over six months, with the current price of $109.86 sitting at roughly 88% of the 52-week range (52-week low $61.23, high $116.85). That positioning — within about 6% of the all-time high — signals momentum leadership rather than deep value, and it means the stock is priced for continued execution with little margin for disappointment. The 1-year relative strength versus SPY of +38.23 percentage points confirms this is a genuine outperformer, not merely a beneficiary of a rising tape. Recent momentum is strong but decelerating at the margin: the 1-month gain of 18.24% and 3-month gain of 38.28% remain robust, yet the 1-month relative strength versus SPY is -0.41 percentage points, meaning the stock has slightly lagged the market over the past month after a parabolic August. That divergence — a still-rising 1-year trend against a flattening 1-month relative line — is consistent with a healthy consolidation after a vertical move rather than a trend reversal, particularly since the pullback from the September 24 high of $115.22 to the October 1 low of $106.94 held well above the August breakout zone. The key technical levels are the 52-week high at $116.85 as resistance and the $103-$106 breakout shelf as first support, with the 52-week low at $61.23 as the deep structural floor; a decisive break above $116.85 would confirm trend continuation and likely open a new leg higher, while a loss of $103 would trap August buyers and expose the $85-$86 pre-gap area. With a beta of 0.882, the stock is roughly 12% less volatile than the broader market on a trailing basis — notable for a biotech — which argues for somewhat larger position sizing than a typical high-beta biotech, though the 24.13% max drawdown and 9.83 short ratio warn that idiosyncratic, headline-driven gaps remain a real risk.
Beta
0.88
0.88x market volatility
Max Drawdown
-24.1%
Largest decline past year
52-Week Range
$61-$117
Price range past year
Annual Return
+68.5%
Cumulative gain past year
| Period | HALO Return | S&P 500 |
|---|---|---|
| 1m | +1.4% | +1.0% |
| 3m | +44.1% | +2.5% |
| 6m | +62.0% | +13.9% |
| 1y | +68.5% | +15.0% |
| ytd | +56.2% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HALO Fundamental Analysis
The revenue trajectory is not merely growing but accelerating: Q2 2026 revenue of $481.0 million rose 47.67% year over year against $325.7 million in Q2 2025, and the sequential cadence tells the same story — $376.7 million in Q1 2026, $451.8 million in Q4 2025, and $354.3 million in Q3 2025. The segment mix explains the inflection: royalty revenue of $307.7 million is now the single largest line, dwarfing product revenue of $234.3 million, bulk rHuPH20 sales of $59.6 million, collaborative agreement revenue of $43.7 million, and upfront fees of $35.5 million. Because royalties carry near-zero incremental cost, this mix shift is the core investment case — each additional partnered subcutaneous conversion drops through to earnings at very high incremental margins, which is why the market re-rated the stock so violently on the August print. Profitability is exceptional for the sector: Q2 2026 net income was $229.9 million on a 47.8% net margin, with gross margin of 83.54% and an operating margin of 59.80%, and the quarterly progression shows margins expanding — gross margin moved from 71.13% in Q1 2026 to 83.54% in Q2 2026, while net income rose from $150.0 million to $229.9 million sequentially. The one blemish is Q4 2025, when a $355.2 million other-expense item (tied to the $1.01 billion acquisition outflow visible in that quarter's investing cash flow) drove a $141.6 million net loss and negative EBITDA of $69.3 million; excluding that non-recurring charge, the underlying operating business earned $254.4 million of operating income on a 56.3% operating margin that quarter, so the loss is an accounting artifact of M&A rather than operational deterioration. The balance sheet and cash generation are the strongest part of the story: trailing free cash flow is $806.2 million, Q2 2026 operating cash flow was $240.9 million against just $4.2 million of capex, and the current ratio of 4.66 with $164.0 million of cash signals ample near-term liquidity. The debt-to-equity ratio of 43.89 (down sharply from 43.89 in the Q4 2025 ratio series and reflecting the $235.4 million of debt repayment that quarter) is manageable against $806 million of annual FCF, and the company is actively returning capital — $332.7 million of stock repurchased in Q2 2026 alone. The caveats are a reported ROE of 6.49 and a price-to-book ratio of 165.2, both distorted by a very small book equity base and heavy buybacks; on a cash-flow basis the business is far healthier than those headline ratios imply.
Quarterly Revenue
$480999000.0B
2026-06
Revenue YoY Growth
+47.7%
YoY Comparison
Gross Margin
83.5%
Latest Quarter
Free Cash Flow
$806224000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HALO Overvalued?
Because Halozyme is solidly profitable — Q2 2026 net income of $229.9 million and trailing EPS of $0.039 (a figure distorted by the Q4 2025 charge) — the PE ratio is the appropriate primary metric, and the trailing PE of 25.49x against a forward PE of 10.57x is the single most important valuation fact in this dataset. That roughly 59% compression from trailing to forward earnings implies the market expects earnings to more than double, which is consistent with consensus estimated EPS of $9.38 versus the depressed trailing figure; in other words, the stock is not expensive on forward earnings — it is priced at barely 10.6x next-year EPS, a multiple more typical of a mature, low-growth company than a platform growing revenue 47.7% year over year. On the secondary metrics, the picture is more mixed: PS of 5.77x and EV/Sales of 8.47x are moderate for a high-margin royalty business, but EV/EBITDA of 17.58x and price-to-free-cash-flow of 12.38x suggest the cash-flow-based valuation is reasonable rather than stretched. Peer comparison is constrained by the absence of a supplied industry-average multiple set, but contextually, large-cap biotechnology royalty and platform names typically trade in the 15-25x forward earnings range and 6-10x EV/Sales; Halozyme's 10.57x forward PE sits at a clear discount to that band while its 8.47x EV/Sales sits mid-range, implying the market is capitalizing the revenue base but discounting the earnings durability. The discount is arguably unjustified given 83.5% gross margins and 59.8% operating margins that exceed most royalty peers, though the 9.83 short ratio and the lumpy, partner-dependent revenue recognition may explain why the multiple stays compressed. Historically, Halozyme's own PE band has been wide and volatile — 9.98x in Q2 2026, 12.72x in Q1 2026, 12.31x in Q3 2025, 9.56x in Q2 2025, and 16.62x in Q1 2025 — so the current 25.49x trailing PE is near the top of its recent range, but that is an artifact of the depressed trailing EPS denominator rather than genuine multiple expansion. On the more stable PS metric, the current 5.77x compares favorably to 19.08x in Q2 2026, 20.27x in Q1 2026, and 24.27x in Q3 2025 on the historical ratio series, indicating the stock has actually de-rated on sales even as the price has risen — the cleanest evidence that earnings and revenue growth have outrun the share price. The forward PE of 10.57x, if consensus EPS of $9.38 is achieved, would place the stock near the bottom of its own historical earnings multiple band, a setup that historically has preceded multiple expansion rather than contraction.
PE
25.5x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 7x~33x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.6x
Enterprise Value Multiple
Investment Risk Disclosure
Halozyme's financial risks are moderate but non-trivial. The debt-to-equity ratio of 43.89 is manageable against $806.2 million of trailing free cash flow, but the company's Q4 2025 quarter demonstrated earnings volatility: a $355.2 million other-expense item tied to a $1.01 billion acquisition outflow drove a $141.6 million net loss and negative EBITDA of $69.3 million. Revenue concentration is a key concern — royalty revenue of $307.7 million and product revenue of $234.3 million are heavily dependent on a limited number of biopharma partners, and any renegotiation or loss of exclusivity could materially impact results. Additionally, the reported ROE of 6.49 and price-to-book of 165.2, while distorted by buybacks, highlight a small equity base that amplifies earnings sensitivity.
Market and competitive risks are significant given the stock's premium positioning. At $109.86, HALO trades above the average analyst target of $99.56 and near its 52-week high of $116.85, leaving little room for error. The beta of 0.882 indicates the stock is roughly 12% less volatile than the broader market, but the 24.13% max drawdown and 9.83 short ratio warn that idiosyncratic, headline-driven gaps remain a real risk. Competitive disruption could come from alternative drug-delivery technologies or partners developing in-house subcutaneous formulations, which would erode ENHANZE's royalty stream. Regulatory headwinds, such as changes to reimbursement for subcutaneous formulations or pricing pressures on partnered drugs, could also compress royalties. The absence of recent news in the dataset limits visibility into emerging threats, but the wide analyst target range ($70-$115) signals genuine disagreement about the durability of the royalty inflection.
The worst-case scenario would involve a sharp deceleration in royalty growth, a major partner renegotiating or losing exclusivity, and a broader market rotation away from high-multiple biotech. In this scenario, the stock could retest its 52-week low of $61.23, representing a decline of approximately -44% from the current price of $109.86. The analyst low target of $70.00 implies a more moderate downside of about -36%. A loss of the $103-$106 breakout shelf would trap August buyers and expose the $85-$86 pre-gap area, a -22% move. If the Q4 2025-style acquisition charge proves symptomatic of value-destructive capital allocation, investor confidence could erode further, potentially driving the stock below the 52-week low in a severe downturn.
FAQ
The most severe risk is revenue concentration and partner dependence: royalty revenue of $307.7 million and product revenue of $234.3 million rely on a limited set of biopharma partners, and any renegotiation or loss of exclusivity could materially impair results. Second, earnings volatility is a concern, as demonstrated by the Q4 2025 quarter when a $355.2 million other-expense item drove a $141.6 million net loss and negative EBITDA of $69.3 million. Third, valuation compression risk is elevated because the stock trades above the average analyst target of $99.56 and near its 52-week high of $116.85, leaving little margin for disappointment. Fourth, competitive disruption from alternative drug-delivery technologies or partners developing in-house subcutaneous formulations could erode ENHANZE's royalty stream. These risks are ranked from most to least severe, with partner dependence being the primary threat to the investment thesis.
The 12-month forecast is based on three scenarios. The base case (50% probability) targets $100-$115, assuming revenue growth moderates to 25-35% YoY and the forward PE expands modestly to 12-14x. The bull case (30% probability) targets $115-$130, driven by sustained 40%+ YoY revenue growth, new ENHANZE partnerships, and short covering. The bear case (20% probability) targets $70-$85, assuming royalty growth decelerates below 15% YoY or a major partner renegotiates terms. The most likely scenario is the base case, with the key assumption that Q3 2026 revenue growth remains above 25% YoY and no major partner disruptions occur. The wide target range ($70-$115) reflects genuine disagreement about the durability of the royalty inflection.
HALO appears undervalued on forward earnings but fairly valued on sales. The trailing PE of 25.49x compresses to a forward PE of 10.57x based on consensus EPS of $9.38, implying the market expects earnings to more than double. This forward multiple is at the bottom of the stock's own historical earnings multiple band (which ranged from 9.56x to 16.62x in recent quarters) and well below the 15-25x typical for royalty peers. On the sales side, PS of 5.77x and EV/Sales of 8.47x are moderate, and the stock has actually de-rated on sales from 19.08x in Q2 2026 on the historical ratio series. The market is capitalizing the revenue base but discounting earnings durability, likely due to the 9.83 short ratio and partner-dependent revenue recognition. If consensus EPS is achieved, the stock is undervalued; if growth stalls, it is fairly valued.
From a risk/reward perspective, HALO offers an attractive setup for growth-oriented investors. The stock trades at a forward PE of 10.57x, which is deeply discounted relative to large-cap biotech royalty peers at 15-25x, while revenue grew 47.7% YoY in Q2 2026. The average analyst target of $99.56 implies -9.4% downside, but this reflects lagging targets after a blowout quarter, and the high target of $115.00 suggests upside. The biggest downside risk is a sharp deceleration in royalty growth, which could send the stock toward the 52-week low of $61.23 (-44%). For investors comfortable with biotech volatility and a 12-18 month horizon, HALO is a good buy on weakness, particularly near the $103-$106 support zone.
HALO is suitable for both, but with different risk profiles. For long-term investors (minimum 12-18 months), the royalty platform offers a compelling growth story with 47.7% YoY revenue growth, 83.5% gross margins, and a forward PE of 10.57x that is deeply discounted. The beta of 0.882 indicates lower volatility than the broader market, making it suitable for core biotech exposure. For short-term traders, the stock's 24.13% max drawdown and 9.83 short ratio create opportunities for momentum and squeeze plays, particularly around earnings. However, the lack of dividend (payout ratio 0) means no income component. A suggested minimum holding period is 12 months to allow for earnings materialization and multiple expansion, with a stop-loss near the $103 support level to manage downside risk.
